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p38a (MAPK14) critically regulates the
immunological response and the
production of specific cytokines and
chemokines in astrocytes
U. Lo1, V. Selvaraj1*, J. M. Plane1, O. V. Chechneva1, K. Otsu2 & W. Deng1,3,4
1Department of Biochemistry and Molecular Medicine, University of California, Davis, CA, USA, 2Department of Cardiovascular
Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan, 3Medical College, Hubei
University of Arts and Science, Xiangyang, Hubei, China, 4Shriners Institute for Pediatric Regenerative Medicine, Sacramento, CA,
USA.
In CNS lesions, ‘‘reactive astrocytes’’ form a prominent cellular response. However, the nature of this
astrocyte immune activity is not well understood. In order to study astrocytic immune responses to
inflammation and injury, we generated mice with conditional deletion of p38a (MAPK14) in GFAP1
astrocytes. We studied the role of p38a signaling in astrocyte immune activation both in vitro and in vivo,
and simultaneously examined the effects of astrocyte activation in CNS inflammation. Our results showed
that specific subsets of cytokines (TNFa, IL-6) and chemokines (CCL2, CCL4, CXCL1, CXCL2, CXCL10)
are critically regulated by p38a signaling in astrocytes. In an in vivo CNS inflammation model of
intracerebral injection of LPS, we observed markedly attenuated astrogliosis in conditional GFAPcre
p38a2/2 mice. However, GFAPcre p38a2/2 mice showed marked upregulation of CCL2, CCL3, CCL4,
CXCL2, CXCL10, TNFa, and IL-1b compared to p38afl/fl cohorts, suggesting that in vivo responses to LPS
after GFAPcre p38a deletion are complex and involve interactions betweenmultiple cell types. This finding
was supported by a prominent increase in macrophage/microglia and neutrophil recruitment in GFAPcre
p38a2/2 mice compared to p38afl/fl controls. Together, these studies provide important insights into the
critical role of p38a signaling in astrocyte immune activation.
A
strocytes are the most abundant glial cell type in the CNS. They perform essential regulatory functions
contributing to the maintenance of CNS homeostasis, including extracellular glutamate uptake1, K1 and
H1 buffering2, energy metabolism3, synaptic transmission4, and microcirculation regulation5,6. The CNS
is a relatively immune privileged compartment due to the lack of lymphatic drainage and unique characteristics of
its vasculature. The blood brain barrier (BBB) regulates CNS microcirculation and consists of perivascular
astrocytic endfeet constituting the neurovascular unit together with endothelial cells, pericytes and microglia.
Disruption of the integrity of the BBB is one of the prominent pathological changes seen after CNS injury, and is
induced by complexmolecularmechanisms regulated by cytokines, chemokines, nitric oxide, adhesionmolecules
and matrix metalloproteinases (MMPs)7,8 that interact with components of the neurovascular unit. In particular,
astrocytes in response to CNS injury exhibit a pathological hallmark termed as ‘‘reactive astrogliosis’’. Studies of
reactive astrocyte elimination suggest that astroglial scar formation ameliorates widespread tissue damage9,10, but
detrimental effects by reactive astrocytes in inhibiting oligodendrocyte progenitor cell (OPC) migration and
remyelination have also been reported11,12. Therefore, the outcome of reactive astrogliosis contributing to CNS
neuropathology remains controversial. In response to inflammatory stimuli, astrocytes also produce proinflam-
matory cytokines and chemokines13–16. Studies suggest that astrocyte-derived TNFa and IL-1b exacerbate inflam-
matory responses by inducing BBB disruption through paracrine effects on endothelial cells17–19. Moreover,
astrocytes are also implicated to be a major source of crucial chemokines involved in BBB disruption and
leukocyte recruitment during CNS injury14,20. In particular, monocyte chemotaxis induced by CCL2 results in
BBB breakdown by the downregulation of endothelial tight junction proteins21. CXCL10 promotes T lymphocyte
infiltration into the CNS parenchyma22, whereas CXCL1 facilitates the transmigration of neutrophils across the
BBB23. Taken together, studies on reactive astrogliosis and its regulation of immune cell trafficking suggest a
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significant yet controversial role of astrocytes during CNS inflam-
matory injury. It remains much debated as to whether immune
activation of astrocytes can facilitate or exacerbate the outcome of
CNS injury, and the definitive role of astrocytes contributing to CNS
neuropathology remains to be determined.
The mitogen-activated protein kinase (MAPK) family transduces
signals from the cell membrane to the nucleus in response to a wide
variety of stimuli24. MAPK family members are serine/threonine
protein kinases belonging to (1) p38 MAPKs, (2) extracellular sig-
nal-related kinases 1 and 2 (ERK1/2), and (3) Jun amino-terminal
kinases (JNKs)25–27. p38 MAPK family members (p38a, p38b, p38c
and p38d) are involved in cell cycle regulation, apoptosis, cell deve-
lopment, proliferation and inflammatory responses28–32. Among
these, p38a is considered to be a central regulator of an inflammatory
response in multiple cell types33,34. Downstream substrates of p38a
include transcription factors and protein kinases, leading to diver-
gent signaling cascades that dictate cellular responses to stress and
inflammation35.
Pharmacological studies using p38 MAPK inhibitors indicated
that astrocytes upregulate TNFa and IL-1b through a p38a-
mediated pathway36,37. Through a feedbackmechanism, downstream
effects of TNFa and IL-1b promote subsequent upregulation of
astrocyte-derived chemokines CCL2, CCL5 CXCL2, CXCL8 and
CXCL1015,38,39. Although an essential role of p38a in the astrocyte
immune responses has been suggested in in vitro studies using chem-
ical inhibitors37,40,41, these inhibitors are not particularly specific and
can also inhibit p38b and other enzymes. Therefore, the definitive
role of p38a in the production of specific cytokines and chemokines
in astrocytes has not been examined. Moreover, administration of
p38MAPK inhibitors in vivo also exhibits general therapeutic effects
on CNS injury models42–44. However, due to the complexity of the in
vivo CNS inflammation involving microglia, astrocytes and infiltrat-
ing leukocytes, there is insufficient information with regard to the
cell-type specific immune response downstream of p38a signaling.
Although astrocytes are capable of performing immunological func-
tions during CNS injury, no studies have delineated the specific role
of astrocytic p38a signaling in conditions of in vivo CNS inflam-
mation. To study the p38a-mediated mechanisms in response to in
vivo CNS inflammation, we first deleted the p38a gene in GFAP1
astrocytes in mice. Using this model, we sought to examine p38a-
mediated immunological events during astrocytic immune response
and define the role of astrocytes in CNS inflammation.
Methods
Animals. Mice with floxed alleles of p38a [B6.129-Mapk14,tm1.2Otsu.] were
generated and described previously45. Human glial fibrillary acidic protein – cre
recombinase expressing mice [hGFAP-Cre; FVB-Tg(GFAP-cre)25Mes/J] as well as
the recombination-reporter strain ROSA26-tdTomato(mT)-EGFP(mG)
[Gt(ROSA)26-Sortm4(ACTB-tdTomato,-EGFP)Luo/J] were obtained from the
Jackson Laboratory (Bar Harbor, ME, USA). All mice were maintained in accordance
to the National Institutes of Health’s Guide for the Care and Use of Laboratory
Animals. Experimental protocols used for this study were approved by the
Institutional Animal Care and Use Committee at the University of California, Davis.
Generation and genotyping of transgenic p38afl/fl and GFAPcre p38a2/2 mice.
Conditional GFAP-specific p38a knockout mice were generated using Cre/loxP
recombination system by cross breeding hGFAP-Cre mice (FVB/N background) and
p38a-floxed mice (C57BL/6 background). The hGFAP-Cre positive heterozygous
p38a-floxed mice were then backcrossed to obtain mice homozygous for p38a
(p38afl/fl) mice with and without hGFAP-Cre (GFAPcre). Mice were genotyped using
tail tip DNA at weaning. In brief, tail tips were lysed in buffer containing proteinase K
and processed for DNA extraction by using QIAamp DNA Mini Kit (Qiagen,
Valencia, CA). Purified genomic DNAwas subjected to PCR using BiolaseHTaqDNA
Polymerase (Bioline, Tauton, MA). The genotypes of p38afl/fl and GFAPcrep38a2/2
mice were examined by analyzing two transgenic compositions in genomic DNA,
including hGFAP-Cre and the presence of p38a-floxed alleles using specific primers
(Table S1). Desired genotypes of either p38afl/fl or GFAPcrep38a2/2 mice were
generated for both in vitro primary culture and in vivo experiments.
Primary culture of astrocytes from p38afl/fl and GFAPcrep38a2/2mice. In order to
obtain astrocyte cultures in high purity, we cross bred a double fluorescent Cre-
reporter line, ROSA26-tdTomato(mT)-EGFP(mG)46, with hGFAP-Cre mice. After
cross breeding, the tdTomato gene flanked by two loxP sites is deleted by Cre-loxP
recombination, leading to EGFP expression in specific cell types with activated
hGFAP promoter. We used the P2 progeny to generate astrocyte cultures. The
primary astrocyte cultures were established from the neonatal cerebral cortex using a
method modified from Fasano et al.47. In brief, the cortex was dissected and isolated
from the diencephalon. Meninges and pia mater were carefully removed from the
dorsal and ventral side of the cortex. Cerebral cortex was then separated and made
into single cell suspension by gentle trituration followed by sequential passage
through 100 mm and 40 mm nylon cell strainers. The resulting cells were then plated
on 5% poly-D-lysine coated T75 flasks, and allowed to grow in minimum essential
medium without D-valine (US Biologicals, Swampscott, MA) supplemented with
10% fetal bovine serum (FBS), 1% sodium pyruvate, 1% non-essential amino acid
solution and 1%penicillin-streptomycin solution (all from Invitrogen, Carlsbad, CA).
This mixed glial culture was maintained at 37uC in a humidified incubator with 5%
CO2 for 7–10 days and allowed to reach 90% confluence. Subsequently, loosely
adherentmicroglia and oligodendrocyte progenitor cells were dislodged and removed
by mechanical shaking at 275 rpm for 20 hours in an orbital shaker within the
incubator. The culture was then incubated in medium containing 50 mM L-leucine
methyl ester hydrochloride for 1 hour to completely eliminate residual proliferating
microglia48. The resulting cultures were then trypsinized, counted and passaged onto
cover slips to examine the purity of astrocyte populations under fluorescent
microscope. Astrocytes with activated hGFAP promoter will express EGFP-encoded
green fluorescence protein on the membrane, whereas other contaminating cell types
including microglia, oligodendrocytes, and fibroblasts will show a red fluorescent
appearance due to an inactivated hGFAP promoter. The established protocol was
then used to generate p38afl/fl and p38a2/2 astrocytes derived from p38afl/fl and
GFAPcrep38a2/2 mice, respectively.
In vitro astrocyte cytokine treatments. To examine the specific responses to
interluekin-1b (IL-1b) and lipopolysaccharide (LPS) exposure, p38afl/fl and p38a2/2
astrocyte were seeded onto 35 mm 6-well plates at a density of 5 3 105 cells per well.
At . 90% confluence, astrocytes were treated with serum-free MEM medium for
24 hours and then exposed to IL-1b (100 ng/ml; Millipore, Billerica, MA) or LPS
(100 ng/ml; Sigma, St. Louis, MO). For cytokine treatment studies, astrocytes were
grouped into 3 wells per treatment and treated with either IL-1b for 0, 15, 30, 45, 60,
90 or 120 min, or LPS for 0, 30, 60 or 90 min to examine specific MAPK protein
activation using western blot analysis.
To quantify different cytokine and chemokine gene expression, p38afl/fl and
p38a2/2 astrocytes were seeded in 100 mm dishes at a density of 2.5 3 106 cells per
dish. Astrocytes were kept in culture for 2–4 days to reach ,90% confluence, and
changed into serum-free MEMmedium the day before cytokine treatment. To study
the role of p38a signaling in astrocytic immune responses, we subjected astrocytes to
IL-1b (30 ng/ml), interferon-c (100 ng/ml, Millipore, Billerica, MA) or LPS (100 ng/
ml) treatments for 0, 2, 4 or 6 hours, and examined immune gene expression using a
real-time quantitative reverse transcriptase-polymerase chain reaction (qPCR)
approach.
Western blot analysis.Astrocytes treated with either IL-1b or LPS for indicative time
points were grouped from 3 wells of 6-well plates and lysed by RIPA buffer
supplemented with protease and phosphatase inhibitors (Roche, Indianapolis, IN).
Cell lysates were resuspended by adding sample buffer containing 0.5 MTris, sodium
dodecyl sulphate (SDS), glycerol, dithiothreitol (DTT) and bromophenol blue.
Samples were then boiled for 5 min, spun down to collect condensation and subjected
to 10% SDS-PAGE. Gels were transferred to a PVDFmembrane and immunoblotted
with the following primary antibodies (from Cell Signaling Technology, Danvers,
MA): phospho-p38MAPK (Thr180/Tyr182) (Catalog # 4511), p38MAPK (Catalog #
9212), phospho-SAPK/JNK (Thr183/Tyr185) (Catalog # 4668), SAPK/JNK (Catalog
# 9295), phospho-p44/42 MAPK (Erk1/2)(Thr202/Tyr204) (Catalog # 9106), p44/42
MAPK (Erk1/2) (Catalog # 4695), MAPKAPK2 (MAP Kinase-activated protein
kinase-2, Thr222) (Catalog # 3316), and a-tubulin (Santa Cruz Biotechnology, Santa
Cruz, CA) (Catalog # sc-8035). In brief, PVDF membranes were blocked with 5%
non-fat dry milk in Tris-buffered saline Tween 20 (TBST) for 1 hour at room
temperature, and then incubated with primary antibodies in blocking solution for
16 hours at 4uC. After three washes in TBST, membranes were then incubated with
horseradish peroxidase-conjugated secondary antibodies (GE Healthcare,
Piscataway, NJ) for 1 hour at room temperature. Bound secondary antibodies were
visualized by chemiluminescence using Pierce ECL Western Blotting Substrate
(Thermo Scientific, Barrington, IL).
Stereotaxic intracerebral LPS injection. Intracerebral injections of LPS into the
cerebral cortex of p38afl/fl and GFAPcre p38a2/2 mice were performed in a stereotaxic
alignment system (David Kopf Instruments, Tujunga, CA). In brief, twelve-week old
mice were anesthetized with isofluorane and positioned in the stereotaxic frame. A
0.2 mm hole was drilled in the skull of the right hemisphere at coordinates of 2 mm
anterior to bregma and 1.5 mm lateral to the midline. Injection of LPS (2 mg in 2 ml
saline) was performed using a glass micropipette at a depth of 1.8 mm below the
duramater using the nanoject II (Drummond Scientific, Broomall, PA). After 6, 12 or
24 hours mice were transcardially perfused with PBS and a 2 mm cylindrical core
sample of tissue was collected from the injection site for mRNA extraction. For
immunohistochemistry, PBS perfusion was followed by 4% formaldehyde and the
whole brain was processed for histology.
www.nature.com/scientificreports
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qPCR for gene expression. We used a qPCR approach to quantify the relative
immune gene expression and compare either between p38afl/fl and p38a2/2 astrocytes
in response to IL-1b, IFNc or LPS exposure, or between p38afl/fl and GFAPcre p38a2/2
mice after intracerebral LPS injection. Total RNA was isolated and purified from
either astrocytes or cylindrical core brain samples using the RNeasy lipid tissue mini
kit (Qiagen). The concentration and quality of RNAwasmeasured using a Nanodrop
spectrophotometer (Nanodrop, Wilmington, DE), and the purity of RNA is verified
by using the OD260/280 ratio between 1.9 and 2.1. Purified RNA (1.0 mg) was
reverse-transcribed to cDNA using a Multiscribe TaqMan reverse transcription
reagent kit (Applied Biosystems, Carlsbad, CA) with an oligo(dT) 15 Primer
(Promega, Madison,WI). Subsequent qPCR reactions for CCL2, CCL3, CCL4, CCL5,
CXCL1, CXCL2, CXCL10, IL-6, IL-1b, TNFa, COX-2, ICAM-1, VCAM-1, GFAP,
Ly6G, CD11b and CD68 were performed in triplicate on a Roche Lightcycler 480
using Quantifast SYBR Green PCR kit (Qiagen) with specific primer sets listed in
table S2. All experimental samples were analyzed and normalized with the expression
level of Rpl13a, a selected internal control gene which is optimal for cytokine
treatment studies compared toGapdh and Sdha49. Either p38afl/fl astrocytes or p38afl/fl
mice group at 0 hours were prepared as standard control for comparison of in vitro
and in vivo immune gene expression, respectively. Relative quantification of fold-
change was performed comparing Cp values (calculated by 2nd derivative maximum)
from individual mice by applying the 22DDCT method50.
Immunohistochemical staining for infiltrating cell quantification.
Immunocytochemistry was performed to quantify infiltrating lymphocytes in the
CNS parenchyma of p38afl/fl and GFAPcrep38a2/2 mice 24 hours after intracerebral
LPS injection. Mice were anesthetized with intraperitoneal injection of ketamine
(100 mg/kg) and xylazine (10 mg/kg), and then transcardially perfused with PBS
followed by 4% parafomaldehyde. Brains were postfixed in 4% parafomaldehyde
overnight before sectioning into 25 mmsections on a cryostat. In brief, frozen sections
were incubated in blocking solution (5% goat serum with 0.03% Triton X-100) at
room temperature for 1 hour, and then incubated overnight at 4uC with primary
antibodies (anti-rat Iba1, Wako, Richmond, VA; anti-mouse Ly6G, BD Bioscience,
San Jose, CA) prepared in the same blocking solution. Sections were washed in PBS,
and then incubated in the species-appropriate fluorescent-conjugated secondary
antibodies. Sections were counterstained with DAPI, and then coverslipped using
ProlongGoldAnti-Fade reagent (Invitrogen). Stained sections were visualized using a
Zeiss Axiophot 2 photomicroscope (Zeiss, Go¨ttingen, Germany) and a Nikon Eclipse
2000E confocol microscope (Nikon, Melville, NY).
We quantified Ly6G-positive neutrophils in four brain sections/animal in the
region closely adjacent to the LPS injection site. Due to an uneven distribution of
L6G-positive cells throughout different brain regions, we selected four areas per brain
section using the 103 objective of a Zeiss Axiophot 2 photomicroscope. Ly6G pos-
itive cells were visualized and counted within the selected 103 field without the
examiner’s knowledge of genotype. We summed the number of Ly6G-positive cells
from all four areas per section to obtain the total cell number/section. The total Ly6G-
positive cell number per section was averaged and statistically compared between the
p38afl/fl and GFAPcrep38a2/2 genotype.
For microglia/macrophage quantification, we counted Iba1-positive cells present
in the brain region near the LPS injection site. Iba1-positive cells were evenly dis-
tributed throughout the brain, thus, we counted cells from eight sections per animal
adjacent to the LPS injection site. Quantification areas were selected in one area/
section under 103 magnification on a Zeiss Axiophot 2 photomicroscope and Iba1-
positive cells were counted with the examiner blinded to genotype. We pooled the
number of cells/region and obtained an average number of Iba1-positive cells/section
for each mouse. Overall data was statistically compared between the p38afl/fl and
GFAPcrep38a2/2 genotype. Data are representative of three animals each for p38afl/fl
and GFAPcre p38a2/2 genotypes.
Statistical analysis. All data analyses were performed using SigmaPlot 9.0 (San Jose,
CA). Data were represented as the mean 6 standard error of the mean. Each group
had at least 6 mice. Statistical analysis was performed using one-way ANOVA-Tukey
post hoc test for multiple comparisons or student t-test for pair-wise comparisons
between p38afl/fl and GFAPcrep38a2/2 genotypes at the same time point. A value of p
# 0.05 was considered statistically significant.
Results
GFAPcrep38a2/2mice were viable with no phenotypic abnormali-
ties. To study the specific role of p38a in astrocytes, we generated a
conditional GFAP-specific p38a knockout mouse by crossing
hGFAP-Cre [FVB-Tg(GFAP-cre)25Mes/J] mice with p38a-floxed
[B6.129-Mapk14,tm1.2Otsu.] mice. The targeted disruption of
p38a gene in GFAPcrep38a2/2 mice is mediated by Cre-loxP
recombination under the control of hGFAP promoter, and p38a
gene deletion only occurred in specific cell types with an active
hGFAP promoter as illustrated (Fig. 1A). The resulting genotype
of GFAPcrep38a2/2 mice was detected by the presence of homo-
zygous p38a-floxed alleles and being positive for hGFAP-Cre trans-
gene (Fig. 1B). The homozygous p38afl/fl mice without hGFAP-Cre
were indistinguishable from the GFAPcrep38a2/2 littermates in
phenotypic appearance, behavior, and body weights. Histological
examination also did not show any astrocyte-specific develop-
mental defects in the central nervous system. In addition to
Figure 1 | Generation of GFAPCrep38a2/2 mice and establishment of
highly purified p38a2/2 astrocyte cultures. (A)GFAPCrep38a2/2micewere
generated by crossing hGFAP-Cre mice and mice with p38a-floxed alleles.
Schematic shows the targeted genetic locus of p38a gene flanked by two
loxP sites. Deletion of p38a gene is driven by Cre-loxP recombination that
is under the control of hGFAP promoter activity in cells. (B)Genotyping of
GFAPcrep38a2/2 mice demonstrating homozygosity of p38a-floxed allele
and positive expression of hGFAP-Cre transgene. (C) Schematic showing
the ROSA26tdTomato reporter system. Under the control of hGFAP
promoter, Cre recombination occurs leads to excision of tdTomato(mT)
and expression of EGFP(mG) in GFAP-positive cells. This results in the
change ofmembrane-bound red fluorescence (tdTomato) to amembrane-
bound green fluorescence (EGFP) in cells. (D) Pure astrocyte cultures
established from pups from cross breeds of ROSA26-tdTomato(mT)/
EGFP(mG) reporter line and hGFAP-Cre mice. The purity of these
astrocyte cultures was verified by the predominance of EGFP-positive
astrocytes, with rare occurrence of tdTomato-positive cells (hGFAP-Cre
negative; scale bar 5 100 mm). (F) In comparison to astrocyte cultures
derived from p38afl/fl mice, western blot analysis confirmed that the p38a
protein is absent in p38a2/2 astrocyte cultures.
www.nature.com/scientificreports
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studying the in vivo effects of p38a in astrocytes during CNS
inflammation, the generation of these mice also allowed us to
establish p38afl/fl and p38a2/2 astrocyte cultures. Using these cul-
tures, we could examine the immune activity of astrocytes in the
absence of other immune cells and the complex inflammatory
milieu seen in the in vivo CNS.
Pure astrocyte cultures could be established from both p38a2/2
and p38afl/fl astrocytes. We first generated astrocyte cultures using
pups from cross breed of homozygous ROSA26-tdTomato(mT)-
EGFP(mG) and hGFAP-Cre mice, in which, tdTomato gene is
excised by Cre recombinase, leading to EGFP expression in cells
with an active hGFAP promoter (Fig. 1C). We then confirmed the
purity of astrocyte cultures using this double fluorescent reporter
cells in primary culture. After expansion of these cultures, we identi-
fied a confluent population of GFAP1 astrocytes expressing EGFP
that were predominant with no tdTomato positive cells indicating
the absence of contaminating cell types that would includemicroglia,
oligodendrocytes, and fibroblasts (Fig 1D). This protocol could be
consistently reproduced and was used to derive highly pure popula-
tions of astrocytes that could be used for subsequent in vitro
experiments. After astrocyte cultures were made from p38afl/fl and
GFAPcrep38a2/2 mice, we also verified for the absence of p38a
protein expression in p38a2/2 cultures (Fig 1E).
Altered JNK, and ERK 1/2 signaling in IL-1b activated p38a2/2
astrocytes. Cross talk between MAPK signalling pathways com-
monly occurs during cellular response to inflammatory stress. We
examined whether p38a deficiency in astrocytes affects JNK and
ERK1/2 activation in response to IL-1b stimulation. We observed
an early phosphorylation of JNK and ERK1/2 proteins in both
p38afl/fl and p38a2/2 astrocytes at 15 min after IL-1b treatment.
This indicates that p38a deficiency in astrocytes has a minimal
effect on initiating ERK1/2 and JNK signaling. Although phospho-
rylated ERK1/2 was not found in resting p38a2/2 astrocytes, IL-1b
stimulation resulted in a sustained ERK1/2 phosphorylation over
time in both p38afl/fl and p38a2/2 astrocytes. Moreover, ERK1/2
phosphorylation remained at lower levels in p38a2/2 astrocytes
compared to p38afl/fl controls. In contrast, we observed a relatively
enhanced and sustained JNK activation in p38a2/2 astrocytes
indicated by increased phosphorylation levels over the entire dura-
tion of IL-1b exposure compared to an acute drop off of JNK
phosphorylation in p38afl/fl astrocytes (Fig. 2A). This suggests that
the JNK pathway is highly activated by IL-1b in the absence of p38a
signaling in astrocytes.
Reduced MK2 protein levels in p38a2/2 astrocytes in response to
LPS. Studies have shown that p38 MAPKs regulate inflammatory
gene expression through an MK2-dependent AU-rich element
(ARE)-containing mRNA stabilization mechanism51. We examined
whether p38a deficiency has an effect on MK2 expression in astro-
cytes before and during immune activation using LPS. In this study,
we observed that basal levels of MK2 protein in p38a2/2 astrocytes
were undetectable in a western blot compared to p38afl/fl astrocytes
(Fig. 2B). In a time course, immune activation by LPS treatment did
not induce MK2 expression in p38a2/2 astrocytes. Basal levels of
MK2 expression observed in p38afl/fl astrocytes were also unaffected
by LPS treatment. These data suggest that p38a deficiency has a
negative effect on MK2 expression in astrocytes.
Diminished NF-kB activity in p38a2/2 astrocytes in response to
LPS.We next investigated whether p38a deficiency has an effect on
the NF-kB activity in the p38a2/2 or p38afl/fl astrocytes after LPS
stimulation. By immunoblot analysis, we observed that immune
activation by LPS treatment did not induce phosphorylated IkB
kinase (p-IKK) protein in p38a2/2 astrocytes compared to p38afl/fl
astrocytes (Fig. 2C). In the meanwhile, LPS treatment did not induce
degradation of IkBa protein in p38a2/2 astrocytes (Fig. 2C). These
data suggest that NF-kB is involved in p38a regulation of pro-
inflammatory cytokine and chemokine expression in astrocytes.
LPS induces differential cytokine, chemokine and adhesion
molecule expression in p38a2/2 and p38afl/fl astrocytes. We
examined the production of different chemokines CCL2, CCL3,
CCL4, CCL5, CXCL1, CXCL2 and CXCL10 in p38a2/2 and
p38afl/fl astrocytes in response to LPS exposure. CCL2 and
Figure 2 | Western blot analysis of p38, JNK, ERK1/2 MAPK, MK2 and
NF-kB signaling in p38a2/2 and p38afl/fl astrocytes. (A) MAPK signaling
in p38a2/2 astrocytes was examined with western blot analysis after IL-1b
treatment. Exposure to IL-1b led to an acute and enhanced activation of
JNK phosphorylation in p38a2/2 compared to p38afl/fl astrocytes.
Although phosphorylated ERK1/2 was not found in resting p38a2/2
astrocytes, IL-1b stimulation resulted in ERK1/2 phosphorylation over
time but this phosphorylation remained at lower levels compared to
p38afl/fl controls. (B) The MK2 activation in p38a2/2 astrocytes was
examined with western blot analysis after LPS treatment. Exposure to LPS
stimulation showed reduced expression of MK2 in p38a2/2 astrocytes
compared to p38afl/fl astrocytes. (C) The NF-kB activity was examined in
p38a2/2 astrocytes compared to p38afl/fl controls in response to LPS
stimulation. Immunoblot analysis showed that immune activation by LPS
treatment did not induce phosphorylated IkB kinase (p-IKK) protein in
p38a2/2 astrocytes compared to p38afl/fl astrocytes and did not induce
degradation of IkBa protein in p38a2/2 astrocytes compared to p38afl/fl
controls. The gels have been run under the same experimental conditions.
www.nature.com/scientificreports
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CXCL10 mRNA levels were significantly upregulated over time after
LPS treatments in control p38afl/fl astrocytes (p, 0.05). In contrast, a
relativelymoderate but significant change in CXCL10 expressionwas
seen in p38a2/2 astrocytes over time after LPS treatment (p , 0.05;
Fig. 3G), whereas a moderate but significant change of CCL2
expression was only detected in p38a2/2 astrocytes at 6 hours after
LPS treatment (p, 0.05; Fig. 3A). However, this difference in trend
of CCL2 and CXCL10 mRNA expression did not reach significance
when statistically compared between the two genotypes. On the other
hand, both CCL4 and CXCL1 mRNA levels were significantly
upregulated in p38afl/fl and p38a2/2 astrocytes response to LPS
exposure (p , 0.05). In particular, significantly lower expression of
CCL4 was observed in p38a2/2 astrocytes at 2, 4 and 6 hours after
LPS treatment, compared to p38afl/fl astrocytes (p , 0.05; Fig. 3C).
CXCL1 mRNA expression was significantly lower in p38a2/2
astrocytes compared to p38afl/fl astrocytes at 4 and 6 hours after
LPS treatment (p , 0.05; Fig. 3E). On a moderate scale, a
significant upregulation of CCL3, CCL5, and CXCL2 mRNA
expression was seen in both p38a2/2 and p38afl/fl astrocytes over
time after LPS treatment (p , 0.05) with no difference between
the genotypes for any of the time points (Fig. 3B, D and F).
We then examined the expression of IL-6, IL-1b, TNFa, andCOX-
2 in p38a2/2 and p38afl/fl astrocytes after LPS treatment. Expression
of IL-1b mRNA level was significantly upregulated and sustained
throughout the duration of LPS treatment in both p38a2/2 and
p38afl/fl astrocytes (p, 0.05; Fig. 3H). We found no statistical differ-
ences between the two genotypes at any of the three time points for
LPS treatment. A significant upregulation of IL-6 mRNA was
observed in control p38afl/fl astrocytes over time after LPS exposure
(p, 0.05). Only a moderate but significant upregulation of IL-6 was
seen in p38a2/2 astrocytes over time after LPS treatment (p, 0.05).
IL-6 mRNA expression was significantly lower in p38a2/2 astrocytes
compared to p38afl/fl astrocytes at 4 hours after LPS treatment (p ,
0.05; Fig. 3I). There was significant upregulation of TNFa mRNA
expression in both p38a2/2 and p38afl/fl astrocytes in response to LPS
(p , 0.05). TNFa mRNA expression in p38a2/2 astrocytes was sig-
nificantly lower compared to p38afl/fl astrocytes at 4 and 6 hours after
LPS treatment (p , 0.05; Fig. 3J). In response to LPS, there was a
moderate upregulation of COX-2 mRNA seen in p38afl/fl astrocytes,
whereas no distinguishable change of COX-2 mRNA levels was
observed in p38a2/2 astrocytes. COX-2 mRNA expression was sig-
nificantly lower in p38a2/2 astrocytes compared to p38afl/fl astrocytes
at 4 and 6 hours after LPS treatment (p, 0.05; Fig. 3K). This result
suggests that p38a plays a predominant role in regulating IL-6, TNFa
and COX-2 expression in LPS-stimulated astrocytes.
We also examined whether p38a regulates the induction of
ICAM-1 and VCAM-1 in astrocytes after LPS exposure. ICAM-1
showed a trend of upregulation but did not reach statistical signifi-
cance for both p38afl/fl and p38a2/2 astrocytes when compared at
different time points after LPS exposure (Fig. 3L). Similarly, for
VCAM-1, we did not observe any significant differences in mRNA
levels after LPS exposure (Fig. 3M). We also did not detect any
statistically significant differences for ICAM-1 and VCAM-1
expression levels between p38a2/2 and p38afl/fl astrocytes after LPS
treatment.
Interleukin-1b induces differential cytokine, chemokine and
adhesion molecule expression in p38a2/2 and p38afl/fl astrocytes.
We examined the specific effects of IL-1b on the activation of
chemokines CCL2, CCL3, CCL4, CCL5, CXCL1, CXCL2, and
CXCL10 in p38afl/fl and p38a2/2 astrocytes. CCL2 and CXCL1
mRNA levels were significantly upregulated in both p38afl/fl and
p38a2/2 astrocytes after IL-1b treatment (p , 0.05; Figure 4A and
E). However, CCL2 expression was significantly lower in p38a2/2
astrocytes at 6 hours compared to p38afl/fl astrocytes after IL-1b
treatment. (p , 0.05; Fig. 4A). After an upregulation at time
points 2 and 4 hours, CXCL1 mRNA levels dropped in both
genotypes at 6 hours after IL-1b exposure; we found that this
decrease in CXCL1 expression was significantly lower in p38a2/2
astrocytes compared to p38afl/fl astrocytes (p , 0.05; Fig. 4E). A
significant short-term upregulation of CXCL2 was detected in both
p38a2/2 and p38afl/fl astrocytes after IL-1b treatment (p , 0.05).
However, we detected that CXCL2 expression was significantly
lower in p38a2/2 astrocytes at time points 2, 4 and 6 hours after
IL-1b exposure compared to p38afl/fl astrocytes (p , 0.05; Fig. 4F).
CCL3 mRNA levels remained unchanged after IL-1b treatment in
both p38a2/2 and p38afl/fl astrocytes (Fig. 4B). Interestingly, we
found significantly lower basal levels of CCL4 in p38a2/2 and
p38afl/fl astrocytes. After IL-1b exposure, CCL4 appeared to be
upregulated at 2 and 4 hours but was not statistically significant.
Even after 2 hours of IL-1b treatment, CCL4 in p38a2/2 astrocytes
was significantly lower than p38afl/fl astrocytes (p, 0.05; Fig. 4C). A
moderate but significant linear upregulation of CCL5 mRNA
expression was seen in both p38a2/2 and p38afl/fl astrocytes over
time after IL-1b treatment (p , 0.05). However, we did not detect
significant differences between the genotypes for any of the time
points (Fig. 4D). CXCL10 expression showed a similar trend of
upregulation but only reached statistical significance in both
p38afl/fl and p38a2/2 astrocytes at 6 hours after IL-1b exposure
compared to 0 hours (p , 0.05; Fig 4G). We did not detect any
statistically significant differences for CXCL10 expression levels
between p38a2/2 and p38afl/fl astrocytes after IL-1b treatment
(Fig. 4G).
In addition to chemokines, we examined whether p38a has a
regulatory effect on IL-1b-induced COX-2 activation in astrocytes.
Our results showed no differences in COX-2 mRNA expression
either temporal or between p38a2/2 and p38afl/fl astrocytes in res-
ponse to IL-1b treatment (Fig. 4H).We also examined for the activa-
tion of other inflammatory mediators such as TNFa and IL-6 in
p38afl/fl and p38a2/2 astrocytes after IL-1b exposure. IL-6 mRNA
levels were significantly upregulated after 2-, 4- and 6-hour IL-1b
treatments in control p38afl/fl astrocytes (p , 0.05). In contrast, no
significant change in IL-6 expression was seen in p38a2/2 astrocytes
at these time points after IL-1b treatment. In particular, we detected a
significantly lower expression of IL-6 in p38a2/2 astrocytes at 2 and
6 hours after IL-1b exposure compared to p38afl/fl astrocytes (p ,
0.05; Fig. 4J). We found no significant differences in TNFa mRNA
expression over time or between p38afl/fl and p38a2/2 astrocytes in
response to IL-1b exposure (Fig. 4I).
We next examined for the effect of IL-1b treatment on ICAM-1
and VCAM-1 expression in astrocytes. We found moderate but sig-
nificant upregulation of ICAM-1 in both p38afl/fl and p38a2/2 astro-
cytes over time after IL-1b treatment that peaked at 4 hours (p ,
0.05). ICAM-1 levels in p38a2/2 astrocytes at 2 hours after IL-1b
treatment was significantly lower compared to p38afl/fl astrocytes (p
, 0.05; Fig. 4K). Similarly, VCAM-1 showed a trend of upregulation
for the entire duration of IL-1b exposure but did not reach statistical
significance for both p38afl/fl and p38a2/2 astrocytes.We also did not
observe any significant differences in VCAM-1 mRNA levels
between genotypes at the three time points after IL-1b exposure
(Fig. 4L). These data suggest that p38a plays a crucial role during
early induction of ICAM-1 in astrocytes after IL-1b exposure.
Interferon c induces differential cytokine, chemokine and
adhesion molecule mRNA expression in p38a2/2 and p38afl/fl
astrocytes. We examined whether IFNc-induced activation of
astrocytes regulates CCL2, CCL3, CCL4, CCL5, CXCL1, CXCL2,
and CXCL10 gene expression through the p38a signaling pathway.
Our results show that a significant upregulation of CCL2 mRNA
expression was seen in p38afl/fl astrocytes after IFNc treatment (p
, 0.05), whereas in p38a2/2 astrocytes a significant upregulation of
CCL2 was detected only at 6 hours after IFNc treatment (p , 0.05;
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Figure 3 | Cytokine, chemokine and cell adhesion molecule expression in p38a2/2 astrocytes as compared to p38afl/fl astrocytes with LPS treatment.
(A) CCL2. (B) CCL3. (C) CCL4. (D) CCL5. (E) CXCL1. (F) CXCL2. (G) CXCL10. (H) IL-1b. (I) IL-6. (J) TNFa. (K) COX-2. (L) ICAM-1. (M) VCAM-1.
*p , 0.05 and **p , 0.01; data represent mean 6 SEM.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 7405 | DOI: 10.1038/srep07405 6
Fig 5A). Similarly, CXCL10 mRNA levels were significantly
upregulated after 2-, 4- and 6-hour IFNc treatments in control
p38afl/fl astrocytes (p , 0.05), whereas a relatively moderate but
significant change in CXCL10 expression was seen in p38a2/2
astrocytes only at 4 and 6 hours after IFNc treatment (p , 0.05;
Fig 5G). However, these trends of CCL2 and CXCL10 mRNA
expression did not reach statistical significance when compared
between the two genotypes (Fig. 5A and G). For CCL5, mRNA
levels were significantly upregulated at 4 and 6 hours after IFNc
treatment in control p38afl/fl astrocytes (p , 0.05), whereas no
Figure 4 | Cytokine, chemokine and cell adhesion molecule expression in p38a2/2 astrocytes as compared to p38afl/fl astrocytes with IL-1b treatment.
(A) CCL2. (B) CCL3. (C) CCL4. (D) CCL5. (E) CXCL1. (F) CXCL2. (G) CXCL10. (H) COX-2. (I) TNFa. (J) IL-6. (K) ICAM-1. (L) VCAM-1. *p, 0.05;
data represent mean 6 SEM.
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significant change was observed in p38a2/2 astrocytes over time after
IFNc treatment suggesting that CCL5 expression was refractory to
IFNc treatment in p38a2/2 astrocytes. Supporting this observation,
statistics comparing p38a2/2 astrocytes at 2, 4 and 6 hours to p38afl/fl
astrocytes after IFNc exposure showed significant differences
between the two genotypes (p , 0.05; Fig. 5D). Similarly, CXCL1
expression increased significantly in p38afl/fl astrocytes after IFNc
treatment (p , 0.05), but only moderately significant fold-changes
in the expression of CXCL1 were seen in p38a2/2 astrocytes (p ,
0.05). However, CXCL1 expression was significantly lower in
Figure 5 | Cytokine, chemokine and cell adhesion molecule expression in p38a2/2 astrocytes as compared to p38afl/fl astrocytes with IFNc treatment.
(A) CCL2. (B) CCL3. (C) CCL4. (D) CCL5. (E) CXCL1. (F) CXCL2. (G) CXCL10. (H) TNFa. (I) ICAM-1. (J) VCAM-1. *p, 0.05; data represent mean
6 SEM.
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p38a2/2 astrocytes at 2, 4 and 6 hours compared to p38afl/fl
astrocytes (p , 0.05; Fig. 5E). Baseline levels of CCL3 and CXCL2
were significantly lower in p38a2/2 astrocytes compared to p38afl/fl
astrocytes (p , 0.05). In response to IFNc treatment, CCL3 and
CXCL2 levels were significantly downregulated in p38afl/fl
astrocytes; but there were minimal to no effects on p38a2/2
astrocytes. Pairwise comparisons between the two genotypes fold-
change values remained significantly different for 0, 2, 4 and 6 hours
after IFNc exposure (p , 0.05; Fig. 5B and 5F). Similar to trends
observed for CCL3 and CXCL2, we found lower baseline expression
of CCL4 in p38a2/2 astrocytes and no observable upregulation in this
genotype. Although there was upregulation of CCL4 in p38afl/fl
astrocytes after IFNc treatment, this difference did not reach
statistical significance. Despite this general trend, we did not detect
any statistically significant differences for CCL4 expression in
comparisons between p38a2/2 and p38afl/fl astrocytes (Fig. 5C).
We also examined whether p38a regulates TNFa expression dur-
ing an IFNc-induced astrocytic response. A moderate upregulation
of TNFa was observed in p38afl/fl astrocytes at 4 and 6 hours after
IFNc exposure, whereas in p38a2/2 astrocytes, TNFa expression
continued to remain at baseline levels even at 2, 4 and 6 hours after
IFNc treatment. However, this difference in trend of TNFa mRNA
fold-change did not reach statistical significance when compared
between the two genotypes (Fig. 5H).
We next examined the role of p38a in regulating adhesion mole-
cule expression in astrocytes induced by IFNc. We observed a mod-
erate but significant upregulation of both ICAM-1 and VCAM-1 in
p38afl/fl and p38a2/2 astrocytes response to IFNc exposure (p ,
0.05). However, we noted significantly lower upregulation of
ICAM-1 in p38a2/2 astrocytes at 2 and 6 hours after IFNc treatment
compared to p38afl/fl astrocytes (p , 0.05; Fig. 5I). Similarly, a sig-
nificantly lower upregulation of VCAM-1 was seen in p38a2/2 astro-
cytes at 2 and 4 hours after IFNc exposure compared to p38afl/fl
astrocytes (p , 0.05; Fig. 5J). Overall, this data suggests that p38a
plays an essential role in regulating CCL5, CXCL1, ICAM-1 and
VCAM-1 activation in astrocytes exposed to IFNc treatment, while
having a minimal effect on CCL2, CXCL10 and TNFa induction.
Intracerebral LPS injection induces differential cytokine, chemo-
kine and adhesion molecule expression in GFAPcrep38a2/2 mice.
We examined the induction of several specific chemokines. CCL2,
and CXCL10 mRNA levels were significantly upregulated in p38afl/fl
and GFAPcrep38a2/2 mice at 6 and 12 hours after intracerebral LPS
injection (p , 0.05). In comparison between the two genotypes, we
found a significantly higher expression of CCL2 and CXCL10 in
GFAPcrep38a2/2 mice at 6 hours after LPS injection (p , 0.05;
Fig. 6A and 6G). For CCL3, a moderate but significant upregula-
tion was observed in GFAPcrep38a2/2 mice at 6 and 12 hours after
intracerebral LPS injection (p , 0.05), while no observable changes
of CCL3 were seen in p38afl/fl cohorts at these time points. Therefore,
levels of CCL3were also significantly higher in GFAPcrep38a2/2 mice
at 6 and 12 hours after intracerebral LPS injection (p, 0.05; Fig. 6B).
Similarly, CXCL2 mRNA levels were significantly upregulated at 6
and 12 hours in GFAPcrep38a2/2 mice after intracerebral LPS
injection (p , 0.05). Although upregulation was moderate in
p38afl/fl cohorts it was also significant at 6 and 12 hours compared
to 0 hours. Comparing CXCL2 expression between the two geno-
types showed a significantly higher expression in GFAPcrep38a2/2
mice at 6 and 12 hours compared to p38afl/fl cohorts (p , 0.05;
Fig. 6F). For CCL4, significant upregulation was observed in both
GFAPcrep38a2/2 mice and p38afl/fl mice after LPS injections at 6 and
12 hours. When expression levels were compared between the two
genotypes, we found CCL4 expression to be significantly higher in
GFAPcrep38a2/2 mice at both 6 and 12 hours compared to p38afl/fl
cohorts (p , 0.05; Fig. 6C). Expression of CCL5 was significantly
upregulated in both p38afl/fl and GFAPcrep38a2/2 mice in the time
course (6 and 12 hours) after intracerebral LPS injection (p, 0.05).
We found no statistical differences between the two genotypes for
CCL5 at any of the three time points (Fig. 6D). Similarly, expression
of CXCL1 was significantly upregulated in both p38afl/fl and
GFAPcrep38a2/2 mice at 6 and 12 hours after intracerebral LPS
injection (p , 0.05); we detected no statistically significant
differences in CXCL1 levels between the genotypes (Fig. 6E).
In addition to chemokines, we also examined the expression of
TNFa, IL-6, and IL-1b in p38afl/fl and GFAPcrep38a2/2 mice after
intracerebral LPS injections. We found a moderate but significant
upregulation of TNFa mRNA in GFAPcrep38a2/2 mice at 12 hours
after intracerebral LPS injection (p , 0.05), whereas no observable
upregulation of TNFamRNA level were detected in p38afl/fl cohorts
over time after LPS injection. Differences were significant with
higher fold-change in GFAPcrep38a2/2 mice compared to p38afl/fl
cohorts at 6 and 12 hours after LPS injections (p , 0.05; Fig. 6H).
We observed significant upregulation of IL-6 in both p38afl/fl and
GFAPcrep38a2/2 mice over time after LPS injection (p , 0.05).
Although no differences were observed between genotypes at the
peak of IL-6 expression at 12 hours after LPS injection, a significantly
higher expression of IL-6 was detected in GFAPcrep38a2/2 mice at
24 hours after LPS injection, compared to p38afl/fl cohorts (p, 0.05;
Fig. 6I). On the other hand, IL-1b mRNA levels were significantly
upregulated in GFAPcrep38a2/2 mice over time after LPS injection (p
, 0.05). In contrast, a relativelymoderate change in IL-1b expression
was seen in p38afl/fl cohorts at 6 and 12 hours after LPS injection (p,
0.05). In particular, a significantly higher expression of IL-1b was
observed in GFAPcrep38a2/2 mice at 6 and 12 hours after LPS injec-
tion, compared to p38afl/fl cohorts (p, 0.05; Fig. 6J). In vivo evidence
indicated that systemic LPS injection stimulates COX-2 production
within the CNS microvaculature52. We thus examined the COX-2
expression in p38afl/fl and GFAPcrep38a2/2 mice following intracer-
ebral LPS injection. A significant upregulation of COX-2mRNAwas
observed in GFAPcrep38a2/2 mice at 6 and 12 hours after LPS injec-
tion (p , 0.05), while a moderate but significant upregulation of
COX-2 was seen in p38afl/fl cohorts over time after LPS injection
(p , 0.05). In particular, we observed a significantly higher COX-2
mRNA expression in GFAPcrep38a2/2 mice at 6 and 12 hours after
LPS injection, compared to p38afl/fl cohorts (p , 0.05; Fig. 6K).
Interestingly, COX-2 expression levels returned to baseline at
24 hours in the GFAPcrep38a2/2 mice, and were significantly lower
compared to p38afl/fl cohorts at this time point (p, 0.05). Moreover,
ICAM-1 and VCAM-1 are crucial adhesion molecules expressed by
cellular components of CNSmicrovasculature including perivascular
astrocytes53. Therefore, we examined the induction of VCAM-1 and
ICAM-1 in p38afl/fl and GFAPcrep38a2/2mice following intracerebral
LPS injection. ICAM-1 mRNA levels were significantly upregulated
in p38afl/fl and GFAPcrep38a2/2 mice at 12 and 24 hours after intra-
cerebral LPS injection (p , 0.05). Particularly, in comparison with
p38afl/fl cohorts, a significantly higher expression of ICAM-1 was
observed in GFAPcrep38a2/2 mice at 12 and 24 hours after LPS
injection (p , 0.05; Fig. 6L). In contrast, a significant upregulation
of VCAM-1 mRNA expression was seen in both p38afl/fl and
GFAPcrep38a2/2 mice over time and peaked at 6 hours after intra-
cerebral LPS injection (p , 0.05). However, we did not detect sig-
nificant differences of VCAM-1 levels between the genotypes for any
of the time points after LPS injection (Fig. 6M). Therefore, astrocyte
p38a signaling modulates in vivo ICAM-1 expression but not
VCAM-1 expression during an intracerebral LPS challenge. Taken
together, in vivo findings identified significantly higher expression of
specific subsets of chemokines, cytokines, and adhesion molecules in
the CNS of GFAPcre p38a2/2 mice challenged with intracerebral LPS
injection.
To corroborate these results based on mRNA levels using an
alternative approach by immunohistochemical analysis of cytokine
and chemokine expression, we performed and verified the immuno-
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Figure 6 | Chemokine, cytokine and cell adhesion molecule expression in the brain of GFAPCre p38a2/2 mice as compared to p38afl/fl mice after
intracerebral LPS injection. (A) CCL2. (B) CCL3. (C) CCL4. (D) CCL5. (E) CXCL1. (F) CXCL2. (G) CXCL10. (H) TNFa. (I) IL-6. (J) IL-1b. (K) COX-2.
(L) ICAM-1. (M) VCAM-1. *p , 0.05 and **p , 0.01; data represent mean 6 SEM.
www.nature.com/scientificreports
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reactivity of CCL2, CXCL10 and IL-6 in the increased population of
CD681 cells in the brain of GFAPcre p38a2/2 mice compared to
p38afl/fl mice at 6 hours after LPS challenge (Fig. 7A). Quantifica-
tion of immunoreactive cells expressing CCL2, CXCL10 and IL-6
showed the increased expression of CCL2, CXCL10 and IL-6 and
particularly their expression in the increased population of CD681
cells in the brain of GFAPcre p38a2/2 mice compared to p38afl/fl mice
after LPS stimulation (Fig. 7B).
Reduced astrocyte activation in GFAPcrep38a2/2mice after intra-
cerebral LPS injection. After an intracerebral LPS injection, we
measured astrogliosis at the site of injection both indirectly by
using astrocyte-specific mRNA responses and directly by immuno-
histochemical and histomorphological examination of astrocyte
responses. At 12 and 24 hours after injections, we observed a sig-
nificant upregulation of GFAP in both p38afl/fl and GFAPcrep38a2/2
mice (p , 0.05). However, the increases in GFAP mRNA in
GFAPcrep38a2/2 mice were significantly lower compared to p38afl/fl
cohorts at 24 hours after intracerebral LPS injection (p , 0.05;
Fig. 8A). This was consistent with in vitro findings in which
p38a2/2 astrocytes exhibited a relatively lower expression of inflam-
matory genes after LPS, IL-1b or IFNc exposure. Supporting the
qPCR data, immunohistopathology evidence also identified clear
signs of reactive astrogliosis with associated microglia/macrophages
in both GFAPcre p38a2/2 and p38afl/fl mice 24 hours after LPS
injection (Fig. 8B). However, the region of astrocyte activation and
the entire dimensions of the lesion were markedly reduced in
GFAPcrep38a2/2 mice. In p38afl/fl mice, we observed a dense popula-
tion of GFAP-immunoreactive astrocytes with a characteristic
morphology indicative of activation at the site of injection in the
brain cortex. In GFAPcrep38a2/2 mice, the pathology was markedly
less. These findings provide a second line of evidence indicating that
astrocytes deficient in p38a are less responsive to inflammatory
injury.
Enhanced neutrophil infiltration in GFAPcrep38a2/2 mice after
intracerebral LPS injection. To investigate the cellular source of
upregulated chemokines and cytokines in GFAPcrep38a2/2 mice,
we examined the presence and expression levels of Ly6G mRNA
following intracerebral LPS injections. A significant upregulation
of Ly6G mRNA was observed in GFAPcrep38a2/2 mice at 6 and
12 hours after intracerebral LPS injection (p , 0.05), while no
observable upregulation of Ly6G was seen in p38afl/fl cohorts over
time. In comparisons between the two genotypes, we detected a
significantly higher expression of Ly6G mRNA in GFAPcrep38a2/2
mice at 6 hours after LPS injection compared to p38afl/fl cohorts (p,
0.05; Fig. 9A). After the initial increase at 6 hours, Ly6G mRNA
expression returned to near-baseline levels at 12 hours post-LPS
injection. This suggests an acute infiltration of neutrophils
occurred at the CNS of GFAPcrep38a2/2 mice in response to an
intracerebral LPS exposure. Supporting the qPCR data, immuno-
cytochemistry evidence also identified a massive infiltration of
neutrophils existing in both GFAPcre p38a2/2 and p38afl/fl mice
24 hours after LPS injection (Fig. 9B). In particular, accumulation
of Ly6G positive neutrophils surrounding the needle tract region was
apparent in both p38afl/fl and GFAPcre p38a2/2 mice. We observed a
high density of Ly6G positive neutrophils at the perivascular space of
the brain parenchyma in both p38afl/fl and GFAPcre p38a2/2 mice. In
contrast, the distribution of Ly6G positive neutrophils was dispersed
at the cortical region of p38afl/fl and GFAPcre p38a2/2 mice. Quan-
tification of neutrophil infiltrates revealed a significantly increased
number of Ly6G positive neutrophils present at the CNS of GFAPcre
p38a2/2 mice 24 hours post-LPS injection, compared to p38afl/fl
cohorts (p , 0.01; Fig. 8C). Together these data provide strong
evidence that there is significantly higher infiltration of neutrophils
in the CNS of GFAPcrep38a2/2 mice after intracerebral LPS injection,
compared to p38afl/fl cohorts.
Increased microglia/macrophage presence in GFAPcrep38a2/2
mice after intracerebral LPS injection. Using CD11b and CD68
as specific markers for macrophages/microglia, we examined the
inflammation site after intracerebral LPS injection in p38afl/fl and
GFAPcrep38a2/2 mice. A significant upregulation of CD11b and
CD68 mRNA was observed in GFAPcrep38a2/2 mice that increased
with time and peaked at 12 hours after intracerebral LPS injection (p
, 0.05); a relatively moderate but also significant upregulation of
CD11b and CD68 was also seen in the p38afl/fl cohorts after LPS
injection (p , 0.05). Interestingly, this upregulation of CD11b in
Figure 7 | Immunostaining and quantification of chemokine and cytokine protein expression in the brain of GFAPCre p38a2/2 and p38afl/fl mice after
intracerebral LPS injection. (A) The immunoreactivity of CCL2, CXCL10 and IL-6 was observed in the increased population of CD681 cells in the brain
of GFAPcre p38a2/2 mice compared to p38afl/fl mice at 6 hours after LPS stimulation. (B) Quantification of immunoreactive cells expressing CCL2,
CXCL10 and IL-6 and the expression of CCL2, CXCL10 and IL-6 in the population of CD681 cells in the brain of GFAPcre p38a2/2 mice compared to
p38afl/fl mice at 6 hours after LPS stimulation.
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GFAPcre p38a2/2 mice was significantly higher than that observed in
control p38afl/fl mice at 6 hours after LPS injection (p , 0.05;
Fig. 10A). However, while the CD11b expression level for both
genotypes dropped down at 24 hours after LPS injection, we
observed significantly lower CD11b levels in GFAPcre p38a2/2 mice
at this time point, compared to p38afl/fl cohorts (p, 0.05; Fig. 10A).
Corresponding with the expression pattern of CD11b, significantly
higher expression levels of CD68 was observed in GFAPcrep38a2/2
mice at 6 and 12 hours after LPS injection, compared to p38afl/fl
cohorts (p , 0.05; Fig. 10B). This observation corroborated that
both primer sets accurately identified a specific cell type. Taken
together, increased upregulation of CD11b and CD68 indicates
either a more prominent CNS microglial proliferation and/or a
greater number of macrophage infiltrations in the brain of
GFAPcrep38a2/2 mice. To examine the specific tissue pathologies
associated with intracerebral LPS injections, we performed
immunohistochemistry for Iba1-positive macrophages/microglia in
the CNS of both GFAPcre p38a2/2 and p38afl/fl mice. Massive
concentrations of macrophages/microglia were found present at
the injection site in both p38afl/fl and GFAPcre p38a2/2 mice
Figure 8 | Detection of GFAP expression at the CNS site of injury in
GFAPCre p38a2/2 mice after intracerebral LPS injection. (A) After
intracerebral LPS injection, GFAP mRNA was significantly upregulated in
both GFAPcre p38a2/2 mice and p38afl/fl cohorts at 24 hours after LPS
injection (p,0.05). But comparison between genotypes showed that this
increase was significantly lower in GFAPcre p38a2/2 mice compared to
p38afl/fl cohorts (p, 0.05). (B) Strongly GFAP-immunoreactive astrocytes
(green) characteristic of activation or ‘‘astrogliosis’’ were detected at the
LPS injection site. Diffuse activation of Iba1 positive microglia/
macrophage (red) was also observed in the proximity of the lesions. In
GFAPcrep38a2/2 mice, astrocyte activation was markedly attenuated
compared to p38afl/fl cohorts at 24 hours after intracerebral LPS injection.
Iba1 positive cells did not show clustering at the site of injury, but rather
distributed in the CNS parenchyma. Distribution of Iba1 positive
microglia/macrophages was also found prominent in GFAPcrep38a2/2
compared to p38afl/fl mice (scale bar 5 100 mm). Representative images
from the two genotypes are shown. *p, 0.05; data representmean6 SEM.
Figure 9 | Neutrophil infiltration at the CNS site of injury in GFAPCre
p38a2/2 mice after intracerebral LPS injection. (A) After intracerebral
LPS injection, Ly6G mRNA showed significant upregulation in GFAPcre
p38a2/2 mice at 6 hours (p, 0.05); this upregulation was relatively mild
and not significant in p38afl/fl cohort. A significantly higher Ly6G
expression was occurred in GFAPcrep38a2/2 mice at 6 hours compared to
p38afl/fl cohorts (p, 0.05). (B) Ly6G positive neutrophils were detected in
the cortical region, LPS injection site (scale bar 5 100 mm) and
perivascular region (scale bar 5 50 mm) in the brain parenchyma after
intracerebral LPS injection. GFAPcrep38a2/2 mice showed marked
increases in infiltrating neutrophils in all the three regions examined
compared to p38afl/fl mice. (C) Quantification of Ly6G positive cells
showed significantly increased numbers in the brains of GFAPcre p38a2/2
mice compared to p38afl/fl mice. Representative images from the two
genotypes are shown. **p , 0.001; data represent mean 6 SEM.
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(Fig. 10C). Quantification of Iba1 positive cells in this immuno-
pathology revealed that significantly higher number of macro-
phages/microglia were present in the brain parenchyma of
GFAPcrep38a2/2 mice compared to p38afl/fl cohorts 24 hours
after intracerebral LPS injection (p , 0.05; Fig. 10D). Together,
the differential effects between GFAPcrep38a2/2 and p38afl/fl
Figure 10 | Microglia/macrophages at the CNS site of injury in GFAPCrep38a2/2 mice after intracerebral LPS injection (A) After intracerebral LPS
injection, CD11bmRNA showed significant upregulation in GFAPcre p38a2/2 mice at 12 hours (p, 0.05); this upregulation was relatively moderate and
not significant in p38afl/fl cohorts. Comparison between genotypes showed a significantly higher CD11b expression in GFAPcrep38a2/2 mice p38afl/fl
cohorts at 12 hours (p , 0.05). (B) Similarly, CD68 mRNA showed significant upregulation in GFAPcre p38a2/2 mice at 12 hours after LPS injection
(p, 0.05); this upregulation was relativelymoderate and not significant in p38afl/fl cohorts. Comparison between genotypes showed a significantly higher
CD68 expression in GFAPcrep38a2/2 mice compared to p38afl/fl cohorts at 6 and 12 hours (p, 0.05). (C) Iba1 positive cells were distributed in the brain
parenchyma and were not particularly clustered at the site of injury. A more prominent distribution of Iba1 positive microglia/macrophages were
observed in GFAPcre p38a2/2 mice compared to p38afl/fl cohorts at 24 hours after intracerebral LPS injection (scale bar 5 100 mm). (D) Numerical
quantification of Iba1 positive cells showed a significant increase in their numbers in GFAPcre p38a2/2 mice compared to p38afl/fl control mice. *p, 0.05;
data represent mean 6 SEM.
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mice highlight an important facet for p38a signaling in CNS
inflammation.
In addition to neutrophil and macrophages/microglia, we inves-
tigated whether intracerebral LPS injection promoted T lymphocyte
recruitment in the CNS parenchyma of GFAPcre p38a2/2 and p38afl/fl
mice.We examined the expression levels of CD4 and CD8 to identify
T lymphocytes. We found no significant upregulation of CD4 or
CD8 in both GFAPcre p38a2/2 and p38afl/fl mice, compared to the
non-injection p38afl/fl cohorts.
Discussion
Signaling via the p38a pathway is essential for immune response in
multiple cell types. As global p38a knockout mice show embryonic
mortality54,55, the role of p38a in cell type specific responses in vivo
has not been characterized. By generating conditional knockout
mice, we sought to examine astrocyte-specific immune responses
mediated by the p38a pathway. We revealed a critical role of p38a
in the regulation of immunological responses and the production of
specific cytokines and chemokines, and a rather complex role of
astrocytes in immune regulation in the CNS. First, by isolating astro-
cyte-specific responses in vitro, we identified that p38a pathway
critically regulates different cytokines: TNFa and IL-6, and chemo-
kines: CCL2, CCL4, CXCL1, CXCL2 and CXCL10. By interpreting
this information through what is known about the different cytokine
and chemokine regulation, we believe that this regulation by the
p38a pathway is by affecting multiple targets. It has been suggested
that expression of CCL2, CXCL10 and IL-6 is via a NFkB-dependent
mechanism56–58. In dendritic cells, it has been shown that p38 a
activity is required at a very fundamental level for the phosphoryla-
tion and phosphoacetylation of histone H3 on a subset of cytokine
and chemokine gene promoters in order to enhance accessibility to
NFkB binding sites59,60.We found that p38a2/2 astrocytes are refract-
ory to LPS treatment in vitro and there is a direct regulation of CCL2,
CXCL10 and IL-6 by p38a signaling. The regulation of NFkB by
p38a signaling in astrocytes would also induce secondary responses
affecting multiple other effectors and adding to the complexity of the
overall response. Other inflammatory mediators like CCL3, CCL4,
CCL5, IL-1b and VCAM-1, also regulated at least in part by NFkB in
different cell types61–64. CCL3, CCL5 and VCAM-1 induction was
significantly lower in p38a2/2 astrocytes after IFNc treatment, but
induction was not different from p38afl/fl astrocytes after treatment
with LPS or IL-1b. Similarly, CCL4 induction was significantly lower
in p38a2/2 astrocytes after treatment with LPS or IL-1b, but induc-
tion was not different from p38afl/fl astrocytes after treatment with
IFNc. Although these specific effects provide direct clues to regu-
lation of p38a signaling in astrocytes, deciphering the mechanisms
underlying these observations is complicated by crosstalk between
p38a and other immune-mediated signaling pathways that may
result in different transcriptional responses.
Several reports have highlighted potential crosstalk between p38a,
JNK and ERK1/2 pathways in many cell types65,66. p38a and JNK
share an upstream kinase MKK4; in cancer cells, p38a deficiency has
been suggested to cause MKK4 to shift its kinase activity toward JNK
activation67. In astrocytes, we found that JNK activation is enhanced
in p38a2/2 astrocytes, suggesting an aberrant effect in this pathway.
JNK regulates c-Jun phosphorylation that is required for AP-1 tran-
scriptional activation and gene expression68–70. It is known that over-
expression of AP-1 induces ICAM-1and CCL2 up-regulation71, and
that both JNK and c-Jun are required for CCL2 expression72.
Findings from this study showed that up-regulation of ICAM-1
and CCL2 was not completely refractory in p38a2/2 astrocytes, sug-
gesting a potential compensation due to enhanced JNK activation.
Downstream effects of this crosstalk can be explained by the conver-
gence of signaling leading to NFkB regulation.
When examining direct downstream targets of p38a upstream of
NFkB, we detected a significantly lower expression of MK2 protein
expression in p38a2/2 astrocytes. MK2 and MK3 are major protein
kinases directly downstream of p38 MAPKs35, and studies have
shown that p38a signaling is critical for cytokine-induced mRNA
stabilization via MK2 and an AU-rich element (ARE) -targeted
mechanism51. MK2 has been implicated in phosphorylation of
ARE-binding proteins73, and a subsequent p38 MAPK-dependent
stabilization of ARE is required for transcriptional activation of sev-
eral inflammatory genes including IL-6, COX-2, TNFa and
CXCL251,74–76. Similar results have been reproduced in several other
studies that demonstrate a direct link between MK2-mediated phos-
phorylation and the transcription of IL-6, TNFa and CXCL177–80. In
support of regulation mediated by MK2 downstream of p38a signal-
ing, findings in this study showed significant down-regulation of
TNFa, IL-6, CXCL1, CXCL2 and COX-2 in p38a2/2 astrocytes in
response to different inflammatory stimuli. Taking another step in
dissecting the role of p38a signaling in this response, we identified
that LPS, IL-1b or IFNc treatment all lead to a similar downregula-
tion of CXCL1 in p38a2/2 astrocytes. This convergence between
IFNc receptor, IL-1 receptor and toll-like receptor triggered events
suggests a possible role of a common adaptor element like MyD88;
p38a andMK2 have been shown to be required forMyD88-mediated
ARE-containing mRNA activation during chemokine expression81.
Previous studies have demonstrated that MyD88 is an essential
adaptor to transduce signaling cascades relayed from IFNc recep-
tor81, IL-1 receptor82, and the toll-like receptor 4 activity83. Findings
in this study using p38a2/2 astrocytes recapitulated and validated
this mechanism of regulation for CXCL1.
For further understanding of astrocyte regulation of immune
function, we also examined the role of astrocyte p38a signaling in
a more complex neuroinflammation context in vivo. Due to reduced
expression of inflammatory genes observed in p38a2/2 astrocytes in
vitro, we originally anticipated similar outcomes from the intracer-
ebral LPS injection model in GFAPcrep38a2/2 mice. Unexpectedly,
we found that the induction of chemokines: CCL2, CCL3, CCL4,
CXCL2 and CXCL10, and cytokines: TNFa, IL-6 and IL-1b, and
ICAM-1 were significantly higher in the CNS of GFAPcrep38a2/2
mice compared to p38afl/fl cohorts. Investigating the underlying rea-
sons for this discrepancy revealed that GFAPcrep38a2/2 mice had
significantly higher numbers of microglia and infiltrates like macro-
phages and neutrophils at the site of injury. Presence of these
immune cells that were identified by specific markers Ly6G,
CD11b and CD68 was correlated with the increased levels of cyto-
kines and chemokines.
Many in vivo studies have suggested that neutrophils represent a
significant source of chemokines such as CCL3, CCL4, CXCL1,
CXCL8, and CXCL1084,85, which in turn chemoattract monocytes,
dendritic cells, T lymphocytes and more neutrophils23,86. Therefore,
neutrophils play a significant role in recruiting infiltrates at sites
of CNS inflammation. Findings in this study indicated that
GFAPcrep38a2/2 mice undergo acute andmassive infiltration of neu-
trophils in response to CNS immune injury. This infiltration could be
a cellular source that leads to significant up-regulation of CCL3,
CCL4 and CXCL10 highlighting an important secondary effect due
to the deficiency of p38a signaling in astrocytes. Perhaps as part of
this neutrophil effect or an independent regulation, GFAPcrep38a2/2
mice develop a more prominent CNS microglia/macrophage res-
ponse. Even though there are no markers to distinguish activation
of resident microglia and the infiltrating macrophage populations,
this observation reveals a clear difference of microglial/macrophage
response in GFAPcrep38a2/2 mice in response to LPS. In vitro studies
have shown that microglia/macrophages can produce TNFa and IL-
1b in response to LPS stimulation87. Previous studies have also
shown that microglia can produce CCL2, CCL3, CCL4, CCL5 and
CXCL1013,14,88,89, and macrophages can produce CCL2, CXCL1,
CXCL890, in response to in vitro TNFa exposure. Therefore, in-
creased microglial/macrophage activation observed in GFAPcrep38a2/2
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mice could also contribute to the elevated levels of different cytokines
and chemokines, adding to effects brought about by increased neu-
trophil infiltration.
We also observed a significant up-regulation of ICAM-1 in the
CNS of GFAPcrep38a2/2 mice after LPS injections. It is well docu-
mented that interaction between ICAM-1 and b2 integrin CD11b/
CD18 (MAC-1) is important for leukocyte transmigration at CNS
inflammation sites91,92. This provides indirect evidence that there is a
concurrent increase in macrophage infiltration in GFAPcrep38a2/2
CNS in addition to neutrophils, rather than a singular effect brought
about by microglia. Altogether, our findings indicate that the defi-
ciency of p38a attenuates an astrocytic response in vitro and results
in an exacerbated CNS inflammatory response in vivo.
We directly examined astrocyte activation or ‘‘reactive astroglio-
sis’’ in vivo and showed an increase in GFAP expression both at the
mRNA level and by immunohistopathology, suggesting that astro-
cytes in GFAPcrep38a2/2 mice were less responsive to inflammatory
stress. This attenuation of astrocyte activity due to the deficiency of
p38a interestingly led to robust neutrophil and microglial/macro-
phage recruitment to the site of CNS injury. In addition to providing
significant insight into the specific role of p38a signaling in astrocyte
activation during CNS inflammation, these findings show direct
evidence that reactive astrocytes have a protective role restricting
inflammation in the CNS.
We observed reduced inflammatory gene expression in p38a2/2
astrocytes in vitro, but higher expression of chemokines CCL2,
CCL3, CCL4, CXCL2, CXCL10 and cytokines TNFa, IL-6, IL-1b
as well as adhesion molecule ICAM-1 in the CNS of GFAPcrep38a2/2
mice after intracerebral LPS injection compared to p38afl/fl cohorts
in vivo. Owing to the complexity of in vivo CNS inflammatory
milieu, the source of upregulated proinflammatory cytokines, che-
mokines and adhesion molecules could be derived from multiple
cellular components other than p38a2/2 astrocytes in the CNS of
GFAPcrep38a2/2 mice. We found crucial evidence demonstrating a
significantly increased expression of infiltrating cell markers such as
Ly6G, CD11b and CD68 in the CNS of GFAPcrep38a2/2 mice, com-
pared to p38afl/fl cohorts, indicating that in vivo p38a2/2 astrocytes
with attenuated immune reactivity lost the capacity to maintain an
intact astroglial barrier and thus result in an exacerbated permeab-
ility for leukocyte extravasation in the CNS parenchyma of
GFAPcrep38a2/2 mice.
In accordance with attenuated astrogliosis of p38a2/2 astrocytes in
vivo, a paralleled upregulation between infiltrating cell markers and
subsets of specific chemokines and cytokines in GFAPcrep38a2/2
mice together confirmed that resident microglia, infiltrating neutro-
phils and macrophages are rather the major contributors of signifi-
cantly upregulated proinflammatory cytokines and chemokines in
the CNS of GFAPcrep38a2/2 mice. Our data demonstrates a signifi-
cantly increased expression of neutrophil marker Ly6G paralleled
with significant upregulation of CCL3, CCL4 and CXCL10 in the
CNS parenchyma of GFAPcrep38a2/2 mice at identical time points
after LPS injection, this suggests the cellular source of significantly
upregulated CCL3, CCL4 and CXCL10 transcripts may be mainly
derived from infiltrating neutrophils, rather than p38a2/2 astrocytes
in the CNS of GFAPcrep38a2/2 mice. Following neutrophil invasion,
macrophages and lymphocytes are the next infiltrating cell types
recruited by the chemokines secreted from neutrophils or CNS res-
ident cell types. A significantly increased amount of macrophage/
microglia in the CNS parenchyma of GFAPcrep38a2/2 mice suggests
either a more prominent CNS microglial proliferation or enhanced
macrophage recruitment after intracerebral LPS injection. Thus,
an elevated number of macrophages/microglia in the CNS of
GFAPcrep38a2/2 mice may contribute to an increased upregulation
of chemokines CCL2, CCL3, CCL4, CXCL10, and cytokine TNFa
observed in GFAPcrep38a2/2 mice after LPS injection. Moreover,
upregulation of ICAM-1 and CD11b in the CNS of GFAPcrep38a2/2
mice both peaked at 12 hours following intracerebral LPS injection.
Interaction between ICAM-1 and b2 integrin CD11b/CD18 (MAC-
1) is considered as an important component for leukocyte trans-
migration at CNS inflammation sites, suggesting that ICAM-1 upre-
gulation has an indispensable role in an increased accumulation of
CD11b1 macrophages/microglia in the CNS parenchyma of
GFAPcrep38a2/2 mice. Particularly, a significant upregulation of
CD11b and CD68 in the CNS of GFAPcrep38a2/2 mice may be
partially derived from an additional recruitment of peripheral
macrophages facilitated by an increased ICAM-1 expression.
Overall, we demonstrated consistency between in vitro and in vivo
results in that astrocytes with p38a ablation are less reactive to
inflammatory stimuli under both conditions. An attenuated immune
reactivity of p38a2/2 astrocytes in vivo specifically indicates the rel-
evance between diminished reactive astrogliosis and impaired astro-
glial barrier in the CNS of GFAPcrep38a2/2 mice. Meanwhile, in
accordance with significantly increased Ly6G, CD68, and CD11b
expression in the CNS of GFAPcrep38a2/2 mice, a contrasting result
emerged between in vitro and in vivo inflammatory gene expression
level together confirmed that microglia, infiltrating neutrophils and
macrophages act as major contributors to those significantly upre-
gulated cytokine and chemokinemRNAs in the CNS of GFAPcrep38a2/2
mice, rather than in vivo p38a2/2 astrocytes with less immune react-
ivity. Particularly, the phenomenon of significantly increased
immune infiltrates in the brain parenchyma of GFAPcrep38a2/2 mice
strongly suggests that the capacity of astrocytes in maintaining the
CNS microvasculature barrier may be impaired due to p38a
deficiency. On the other hand, this indicates that astrocyte p38a
signaling may perform a more profound effect on regulating CNS
microvasculature, rather than modulating immunological events
under in vivo CNS inflammatory conditions.
We generated the conditional GFAP-specific p38a knockout
mouse in order to study the definitive role of astrocyte p38a signaling
under in vivo CNS inflammatory conditions. However, neurons
derived from the neuroectoderm lineage underwent a GFAP-
expression stage and have also been conditionally knocked-out of
p38a during early neurogenesis93. Moreover, adult neurogenesis has
been suggested to be mainly derived fromGFAP-expressing progen-
itor cells94,95. Thus, there exists a p38a2/2 neuron population in addi-
tion to p38a2/2 astrocytes in the CNS of these GFAPcrep38a2/2 mice.
During in vitro studies, the process of generating pure astrocyte
cultures eliminated the p38a2/2 neurons and p38a2/2 neural pro-
genitor cells through a sequential procedure of mechanical dislodge-
ment, trypsinization and L-leucine methyl ester hydrochloride
treatment. Therefore, a very minimal existence of p38a2/2 neurons
does not interfere with the in vitro immune activity of p38a2/2 astro-
cytes in response to inflammatory stimulation. However, an inev-
itable existence of p38a2/2 neurons in the CNS of GFAPcrep38a2/2
mice might exhibit an additional effect on the in vivo CNS inflam-
matory response. Therefore, the existence of p38a deficient neurons
and their response to LPS injection should also be considered as a
potential factor contributing to the increased chemokine and cyto-
kine upregulation in GFAPcrep38a2/2 mice in response to LPS-
mediated inflammatory insults. Thus, neurons have the capacity to
respond to an inflammatory stress via p38MAPK signaling pathways
and neurons with p38a ablation could be less vulnerable in response
to inflammatory exposure in vivo. In our GFAPcrep38a2/2 mouse
model, neurons with p38a deficiency being less responsive to LPS-
induced inflammatory stress may reduce its production of cytotoxic
signal molecules, leading to an attenuated astroglial reactivity under
conditions of in vivo CNS inflammation. Taken together, an attenu-
ated reactive astrogliosis in vivo due to either astrocyte or neuronal
p38a deficiency may contribute to an impaired astroglial barrier at
the CNS perivascular space, and consequently result in a massive
leukocyte infiltration in the brain parenchyma of GFAPcrep38a2/2
mice following intracerebral LPS injection.
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In conclusion, we identified a specific role of p38a in regulating
specific subsets of inflammatory genes during an astrocytic immune
response, and that astrocytes with p38a ablation are less responsive
to inflammatory stress under both in vivo and in vitro conditions.
Under CNS inflammatory conditions, a diminished reactivity of
astrogliosis in GFAPcrep38a2/2 mice is suggested to impair the
formation of astroglial barrier and abolish the effect on restricting
leukocyte infiltration. Taken together, our findings reveal the signifi-
cance of in vivo astrocyte p38a signaling inmaintaining the barrier of
CNS microcirculation, which is more crucial than modulating
immunological events under CNS pathological conditions. Overall,
this study not only highlights the importance of p38a signaling in
astrocyte immune activation in vitro, but also provides mechanistic
insight into understanding the cell-specific p38a signaling in
the cellular components of neurovascular unit during CNS neuro-
inflammation. By investigating astrocyte function using the
GFAPcrep38a2/2 mouse model, we resolve a long-existing contro-
versy in the field regarding the outcome of astrocyte activation by
providing direct evidence that reactive astrogliosis restricts the sever-
ity of inflammation in the injured CNS.
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